{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:27:00Z","timestamp":1793158020341,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01686-y","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T12:12:09Z","timestamp":1756296729000},"page":"1170-1184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions"],"prefix":"10.1007","volume":"27","author":[{"given":"Eric H.","family":"Bent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"1","key":"1686_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1686_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701\u201311. https:\/\/doi.org\/10.1038\/nrc4016.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"1686_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312. https:\/\/doi.org\/10.1056\/NEJMoa040720.","journal-title":"N Engl J Med"},{"issue":"26","key":"1686_CR4","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019;381(26):2506\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1911206.","journal-title":"N Engl J Med"},{"issue":"12","key":"1686_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"1686_CR6","doi-asserted-by":"publisher","unstructured":"Sollini M, Calais J, Chiti A, et al. Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.036","DOI":"10.1016\/j.eururo.2024.09.036"},{"key":"1686_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_350946","volume":"42","author":"A Gafita","year":"2022","unstructured":"Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. Am Soc Clin Oncol Educ Book. 2022;42:1\u201317. https:\/\/doi.org\/10.1200\/EDBK_350946.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"1686_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"1686_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19(9):589\u2013608. https:\/\/doi.org\/10.1038\/s41573-020-0073-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1686_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1213755.","journal-title":"N Engl J Med"},{"issue":"12","key":"1686_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","volume":"16","author":"MJ Morris","year":"2019","unstructured":"Morris MJ, Corey E, Guise TA, et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019;16(12):745\u201356. https:\/\/doi.org\/10.1038\/s41585-019-0251-x.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"1686_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","volume":"20","author":"M Smith","year":"2019","unstructured":"Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(18)30860-X.","journal-title":"Lancet Oncol"},{"key":"1686_CR13","doi-asserted-by":"publisher","unstructured":"Gillessen S, Tombal B, Turco F, et al. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333\/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. Eur Urol. 2025. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.027","DOI":"10.1016\/j.eururo.2024.11.027"},{"issue":"8","key":"1686_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","volume":"19","author":"L Bodei","year":"2022","unstructured":"Bodei L, Herrmann K, Schoder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534\u201350. https:\/\/doi.org\/10.1038\/s41571-022-00652-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 3","key":"1686_CR15","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.2967\/jnumed.121.262749","volume":"62","author":"J Capala","year":"2021","unstructured":"Capala J, Graves SA, Scott A, et al. Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources. J Nucl Med. 2021;62(Suppl 3):3S-11S. https:\/\/doi.org\/10.2967\/jnumed.121.262749.","journal-title":"J Nucl Med"},{"key":"1686_CR16","doi-asserted-by":"publisher","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2024. https:\/\/doi.org\/10.1038\/s41585-024-00900-z","DOI":"10.1038\/s41585-024-00900-z"},{"issue":"3","key":"1686_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00259-022-05982-8","volume":"50","author":"L Lucaroni","year":"2023","unstructured":"Lucaroni L, Georgiev T, Prodi E, et al. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics. Eur J Nucl Med Mol Imaging. 2023;50(3):957\u201361. https:\/\/doi.org\/10.1007\/s00259-022-05982-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1686_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.euf.2021.03.012","volume":"7","author":"NM Keegan","year":"2021","unstructured":"Keegan NM, Bodei L, Morris MJ. Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer. Eur Urol Focus. 2021;7(2):267\u201378. https:\/\/doi.org\/10.1016\/j.euf.2021.03.012.","journal-title":"Eur Urol Focus"},{"issue":"5B","key":"1686_CR19","first-page":"927","volume":"7","author":"JS Horoszewicz","year":"1987","unstructured":"Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res Sep-Oct. 1987;7(5B):927\u201335.","journal-title":"Anticancer Res Sep-Oct"},{"issue":"1","key":"1686_CR20","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1686_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2967\/jnumed.121.262997","volume":"63","author":"AK Miyahira","year":"2022","unstructured":"Miyahira AK, Soule HR. The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation. J Nucl Med. 2022;63(3):331\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.262997.","journal-title":"J Nucl Med"},{"issue":"17","key":"1686_CR22","first-page":"3629","volume":"57","author":"H Liu","year":"1997","unstructured":"Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57(17):3629\u201334.","journal-title":"Cancer Res"},{"issue":"3","key":"1686_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1021\/jm000406m","volume":"44","author":"AP Kozikowski","year":"2001","unstructured":"Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001;44(3):298\u2013301. https:\/\/doi.org\/10.1021\/jm000406m.","journal-title":"J Med Chem"},{"issue":"24","key":"1686_CR24","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","volume":"17","author":"Y Chen","year":"2011","unstructured":"Chen Y, Pullambhatla M, Foss CA, et al. 2-(3\u20131-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17(24):7645\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1357.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1686_CR25","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688\u201397. https:\/\/doi.org\/10.1021\/bc200279b.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"1686_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1148\/radiol.2021202771","volume":"299","author":"C Lawhn-Heath","year":"2021","unstructured":"Lawhn-Heath C, Salavati A, Behr SC, et al. Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021;299(2):248\u201360. https:\/\/doi.org\/10.1148\/radiol.2021202771.","journal-title":"Radiology"},{"issue":"6","key":"1686_CR27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019;5(6):856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1686_CR28","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021;7(11):1635\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771.","journal-title":"JAMA Oncol"},{"issue":"13","key":"1686_CR29","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic Performance of (18)F-DCFPyL-PET\/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III. Multicenter Study Clin Cancer Res. 2021;27(13):3674\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4573.","journal-title":"Multicenter Study Clin Cancer Res"},{"issue":"1","key":"1686_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, et al. A Phase 2\/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET\/CT with (18)F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol. 2021;206(1):52\u201361. https:\/\/doi.org\/10.1097\/JU.0000000000001698.","journal-title":"J Urol"},{"issue":"21","key":"1686_CR31","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","volume":"23","author":"NH Bander","year":"2005","unstructured":"Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21):4591\u2013601. https:\/\/doi.org\/10.1200\/JCO.2005.05.160.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1686_CR32","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2004.09.154","volume":"22","author":"MI Milowsky","year":"2004","unstructured":"Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2522\u201331. https:\/\/doi.org\/10.1200\/JCO.2004.09.154.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1686_CR33","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00259-014-2978-1","volume":"42","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Giesel FL, Eder M, et al. 177Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(6):987\u20138. https:\/\/doi.org\/10.1007\/s00259-014-2978-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1686_CR34","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2967\/jnumed.119.236414","volume":"61","author":"J Violet","year":"2020","unstructured":"Violet J, Sandhu S, Iravani A, et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of (177)Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020;61(6):857\u201365. https:\/\/doi.org\/10.2967\/jnumed.119.236414.","journal-title":"J Nucl Med"},{"issue":"6","key":"1686_CR35","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1686_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of (177)Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med. 2019;60(4):517\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.219352.","journal-title":"J Nucl Med"},{"issue":"6","key":"1686_CR37","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(6):597\u2013610. https:\/\/doi.org\/10.1016\/S1470-2045(23)00158-4.","journal-title":"Lancet Oncol"},{"issue":"10276","key":"1686_CR38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"issue":"12","key":"1686_CR39","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1686_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25(1):99\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(23)00529-6.","journal-title":"Lancet Oncol"},{"issue":"10459","key":"1686_CR41","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2.","journal-title":"Lancet"},{"issue":"25","key":"1686_CR42","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","volume":"36","author":"G Attard","year":"2018","unstructured":"Attard G, Borre M, Gurney H, et al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol. 2018;36(25):2639\u201346. https:\/\/doi.org\/10.1200\/JCO.2018.77.9827.","journal-title":"J Clin Oncol"},{"issue":"suppl_2","key":"1686_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/annonc\/annonc1623","volume":"35","author":"O Sartor","year":"2024","unstructured":"Sartor O, Jiang DM, Smoragiewicz M, et al. Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). Annals Oncol. 2024;35(suppl_2):1\u201372. https:\/\/doi.org\/10.1016\/annonc\/annonc1623.","journal-title":"Annals Oncol"},{"issue":"16\\_suppl","key":"1686_CR44","doi-asserted-by":"publisher","first-page":"TPS5116","DOI":"10.1200\/jco.2023.41.16_suppl.tps5116","volume":"41","author":"ST Tagawa","year":"2023","unstructured":"Tagawa ST, Sartor OA, Saad F, et al. PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2023;41(16\\_suppl):TPS5116\u2013TPS5116. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.tps5116.","journal-title":"J Clin Oncol"},{"key":"1686_CR45","doi-asserted-by":"publisher","unstructured":"Gillessen S, Turco F, Davis ID, et al. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.017","DOI":"10.1016\/j.eururo.2024.09.017"},{"key":"1686_CR46","doi-asserted-by":"publisher","unstructured":"Sayar E, Patel RA, Coleman IM, et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023;8(7). https:\/\/doi.org\/10.1172\/jci.insight.162907","DOI":"10.1172\/jci.insight.162907"},{"issue":"5","key":"1686_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku SY, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699\u2013715. https:\/\/doi.org\/10.1038\/s43018-023-00539-6.","journal-title":"Nat Cancer"},{"issue":"2","key":"1686_CR48","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, et al. Quantitative (68)Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following (177)Lu-PSMA-617 (VISION Trial). Radiology. 2024;312(2):e233460. https:\/\/doi.org\/10.1148\/radiol.233460.","journal-title":"Radiology"},{"key":"1686_CR49","doi-asserted-by":"publisher","first-page":"102862","DOI":"10.1016\/j.eclinm.2024.102862","volume":"77","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Gafita A, de Bono JS, et al. Multivariable models of outcomes with [(177)Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. EClinicalMedicine. 2024;77:102862. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102862.","journal-title":"EClinicalMedicine"},{"issue":"8","key":"1686_CR50","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, et al. Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22(8):1115\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1686_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","volume":"5","author":"D De Ruysscher","year":"2019","unstructured":"De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. Radiotherapy toxicity. Nat Rev Dis Primers. 2019;5(1):13. https:\/\/doi.org\/10.1038\/s41572-019-0064-5.","journal-title":"Nat Rev Dis Primers."},{"issue":"9","key":"1686_CR52","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nrc1950","volume":"6","author":"SM Bentzen","year":"2006","unstructured":"Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6(9):702\u201313. https:\/\/doi.org\/10.1038\/nrc1950.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1686_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","volume":"52","author":"P Jackson","year":"2022","unstructured":"Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi KA. Radiation Dosimetry in (177)Lu-PSMA-617 Therapy. Semin Nucl Med. 2022;52(2):243\u201354. https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.11.003.","journal-title":"Semin Nucl Med"},{"issue":"5","key":"1686_CR54","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2967\/jnumed.122.264594","volume":"64","author":"J Brosch-Lenz","year":"2023","unstructured":"Brosch-Lenz J, Delker A, Volter F, et al. Toward Single-Time-Point Image-Based Dosimetry of (177)Lu-PSMA-617 Therapy. J Nucl Med. 2023;64(5):767\u201374. https:\/\/doi.org\/10.2967\/jnumed.122.264594.","journal-title":"J Nucl Med"},{"issue":"16\\_suppl","key":"1686_CR55","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1200\/jco.2023.41.16_suppl.5046","volume":"41","author":"BJ Krause","year":"2023","unstructured":"Krause BJ, Chi KN, Sartor AO, et al. Tumor dosimetry of 177Lu Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study. J Clin Oncol. 2023;41(16\\_suppl):5046\u20135046. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.5046.","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"1686_CR56","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"1686_CR57","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1200\/JCO.23.01241","volume":"42","author":"AP Kiess","year":"2024","unstructured":"Kiess AP, O\u2019Donoghue J, Uribe C, et al. How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design. J Clin Oncol. 2024;42(15):1734\u20137. https:\/\/doi.org\/10.1200\/JCO.23.01241.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1686_CR58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1686_CR59","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2967\/jnumed.111.094235","volume":"53","author":"E Garin","year":"2012","unstructured":"Garin E, Lenoir L, Rolland Y, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT\/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255\u201363. https:\/\/doi.org\/10.2967\/jnumed.111.094235.","journal-title":"J Nucl Med"},{"issue":"2","key":"1686_CR60","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","volume":"18","author":"JG Scott","year":"2017","unstructured":"Scott JG, Berglund A, Schell MJ, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017;18(2):202\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(16)30648-9.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1686_CR61","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S1470-2045(21)00347-8","volume":"22","author":"JG Scott","year":"2021","unstructured":"Scott JG, Sedor G, Ellsworth P, et al. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. Lancet Oncol. 2021;22(9):1221\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(21)00347-8.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1686_CR62","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2967\/jnumed.120.256263","volume":"62","author":"AD Stuparu","year":"2021","unstructured":"Stuparu AD, Capri JR, Meyer CAL, et al. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. J Nucl Med. 2021;62(7):989\u201395. https:\/\/doi.org\/10.2967\/jnumed.120.256263.","journal-title":"J Nucl Med"},{"issue":"12","key":"1686_CR63","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.7150\/thno.96322","volume":"14","author":"PHJ Slootbeek","year":"2024","unstructured":"Slootbeek PHJ, Luna-Velez MV, Prive BM, et al. Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2024;14(12):4555\u201369. https:\/\/doi.org\/10.7150\/thno.96322.","journal-title":"Theranostics"},{"key":"1686_CR64","doi-asserted-by":"publisher","unstructured":"De Bono JS, Morris MJ, Sartor O, et al. Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore. J Clin Oncol. 2024;42(suppl 16). https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5008","DOI":"10.1200\/JCO.2024.42.16_suppl.5008"},{"issue":"11","key":"1686_CR65","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","volume":"3","author":"WR Polkinghorn","year":"2013","unstructured":"Polkinghorn WR, Parker JS, Lee MX, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3(11):1245\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0172.","journal-title":"Cancer Discov"},{"key":"1686_CR66","doi-asserted-by":"publisher","unstructured":"Vaishampayan N, Morris MJ, Krause BJ, et al. [177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial. J Clin Oncol. 2022;40(suppl 16). https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5001","DOI":"10.1200\/JCO.2022.40.16_suppl.5001"},{"issue":"5","key":"1686_CR67","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, et al. [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9.","journal-title":"Lancet Oncol"},{"key":"1686_CR68","doi-asserted-by":"publisher","first-page":"175883592311872","DOI":"10.1177\/17588359231187202","volume":"15","author":"AJ Inderjeeth","year":"2023","unstructured":"Inderjeeth AJ, Iravani A, Subramaniam S, Conduit C, Sandhu S. Novel radionuclide therapy combinations in prostate cancer. Ther Adv Med Oncol. 2023;15:17588359231187202. https:\/\/doi.org\/10.1177\/17588359231187202.","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"1686_CR69","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, Bressel M, Tan H, et al. Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2024;25(10):1267\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(24)00440-6.","journal-title":"Lancet Oncol"},{"key":"1686_CR70","doi-asserted-by":"publisher","unstructured":"Batra JS, Niaz MJ, Whang YE, et al. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177)Lu-J591) for metastatic castration-resistant prostate cancer. Urol Oncol. 2020;38(11):848 e9\u2013848 e16. https:\/\/doi.org\/10.1016\/j.urolonc.2020.05.028","DOI":"10.1016\/j.urolonc.2020.05.028"},{"issue":"9","key":"1686_CR71","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015;1(9):1325\u201332. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2756.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1686_CR72","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487\u2013500. https:\/\/doi.org\/10.1038\/s41590-022-01132-2.","journal-title":"Nat Immunol"},{"issue":"7","key":"1686_CR73","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(14)70189-5.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1686_CR74","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28(1):144\u201353. https:\/\/doi.org\/10.1038\/s41591-021-01600-6.","journal-title":"Nat Med"},{"issue":"11","key":"1686_CR75","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, de Kouchkovsky I, et al. Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023;24(11):1266\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(23)00451-5.","journal-title":"Lancet Oncol"},{"key":"1686_CR76","doi-asserted-by":"publisher","unstructured":"Sandhu S, M JA, L E, et al. PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). J ClinOncol. 2022;40(16\\_suppl):5017-5017. https:\/\/doi.org\/10.1200\/jco.2022.40.16\\_suppl.5017","DOI":"10.1200\/jco.2022.40.16\\_suppl.5017"},{"issue":"17","key":"1686_CR77","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1158\/1078-0432.CCR-21-0063","volume":"27","author":"L Fong","year":"2021","unstructured":"Fong L, Morris MJ, Sartor O, et al. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021;27(17):4746\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0063.","journal-title":"Clin Cancer Res"},{"issue":"16\\_suppl","key":"1686_CR78","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/jco.2023.41.16_suppl.5005","volume":"41","author":"S Sandhu","year":"2023","unstructured":"Sandhu S, Joshua AM, Emmett L, et al. LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41(16\\_suppl):5005\u20135005. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.5005.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1686_CR79","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1535-7163.MCT-22-0583","volume":"22","author":"E Pan","year":"2023","unstructured":"Pan E, Xie W, Ajmera A, et al. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). Mol Cancer Ther. 2023;22(4):511\u20138. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0583.","journal-title":"Mol Cancer Ther"},{"key":"1686_CR80","doi-asserted-by":"publisher","unstructured":"Imber BSaBLaHJaIAaWWaGMaODJaRRP. A Pilot Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for Oligometastatic Hormone Sensitive Prostate Cancer. Int J Radiation Oncol*Biol*Phys. 2023;117(2):e112. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.891","DOI":"10.1016\/j.ijrobp.2023.06.891"},{"key":"1686_CR81","doi-asserted-by":"publisher","unstructured":"Eychenne R, Ch\u00e9rel M, Haddad F, Gu\u00e9rard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The \"Hopeful Eight\". Pharmaceutics. 2021;13(6). https:\/\/doi.org\/10.3390\/pharmaceutics13060906","DOI":"10.3390\/pharmaceutics13060906"},{"key":"1686_CR82","doi-asserted-by":"publisher","first-page":"175883592311576","DOI":"10.1177\/17588359231157632","volume":"15","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023;15:17588359231157632. https:\/\/doi.org\/10.1177\/17588359231157632.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"1686_CR83","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K, et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol. 2021;79(3):343\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.013.","journal-title":"Eur Urol"},{"issue":"2","key":"1686_CR84","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):175\u201383. https:\/\/doi.org\/10.1016\/S1470-2045(23)00638-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1686_CR85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","volume":"7","author":"ME Alcocer-Avila","year":"2020","unstructured":"Alcocer-Avila ME, Ferreira A, Quinto MA, Morgat C, Hindie E, Champion C. Radiation doses from (161)Tb and (177)Lu in single tumour cells and micrometastases. EJNMMI Phys. 2020;7(1):33. https:\/\/doi.org\/10.1186\/s40658-020-00301-2.","journal-title":"EJNMMI Phys"},{"key":"1686_CR86","doi-asserted-by":"publisher","unstructured":"Morris MJ, Wong JYC, Nordquist L, et al. A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42(suppl 16). https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5010","DOI":"10.1200\/JCO.2024.42.16_suppl.5010"},{"issue":"1","key":"1686_CR87","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly WK, Danila DC, Lin CC, et al. Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024;14(1):76\u201389. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0964.","journal-title":"Cancer Discov"},{"issue":"22","key":"1686_CR88","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023;389(22):2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"key":"1686_CR89","doi-asserted-by":"publisher","unstructured":"Aggarwal RR, S R, A B-T, et al. Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). J Clin Oncol. 2024;42(16\\_suppl):5012-5012. https:\/\/doi.org\/10.1200\/jco.2024.42.16\\_suppl.5012","DOI":"10.1200\/jco.2024.42.16\\_suppl.5012"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01686-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01686-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01686-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:58:03Z","timestamp":1760144283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01686-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":89,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1686"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01686-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"6 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.J.M. has served as a consultant to Lantheus, AstraZeneca, Daiichi, Convergent Therapeutics, Pfizer, ITM Isotopes, Clarity Pharmaceuticals, Blue Earth Diagnostics, POINT Biopharma, Telix, Z-Alpha, AMBRX, Flare Therapeutics, Fusion Pharmaceuticals, Curium, Transtherabio, Celgene, Arvinas, Molecular Partners, Advancelle, Isotopia, and Exelixis. His institution receives royalty payments from Telix, and research funding from Novartis, Fusion, and Astellas. E.H.B. has no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All reported human subjects studies performed by the authors have been previously published and complied with all applicable ethical standards (including institutional\/national research committee standards, the Helsinki declaration and its amendments, and international\/national\/institutional guidelines).Figure 1 \u00a9 2025 Memorial Sloan-Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases, and Sloan-Kettering Institute for Cancer Research, each in New York, NY. Al rights reserved. Republished with permission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}